Medication Guide App

Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections

- Activity data on lead NNRTI, RDEA806, and next generation compounds to be discussed -

CARLSBAD, Calif., January 29, 2008 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that preclinical data on the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds, including RDEA806, RDEA427 and RDEA640, will be presented during the 15th Annual Conference on Retroviruses and Opportunistic Infections (CROI) in Boston, February 3-6, 2008.

    The presentation details are as follows:


    Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time

    Title: An IQ Assessment of RDEA806, A Potent NNRTI with an Excellent

           Activity Profile in the Presence of Human Serum Proteins

    Location: Poster Session 123 (Poster # 731) -- Hall A, Hynes Convention

              Center


    Date/Time: Tuesday, February 5, 2008, 1:00 p.m. Eastern Standard Time

    Title: RDEA427 and RDEA640 are Novel NNRTIs with Potent Anti-HIV Activity

           against NNRTI-Resistance Viruses

    Location: Poster Session 123 (Poster # 730) -- Hall A, Hynes Convention

              Center


About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 possesses several attractive properties. These include: potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)), Bristol-Myers Squibb) and other currently available NNRTIs; a high genetic barrier to resistance; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences, Inc.

Ardea Biosciences of Carlsbad, California is a biotechnology company focused on the discovery and development of small-molecule therapeutics in virology, oncology and inflammation. The Company has two product candidates in clinical development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of gout. In oncology, the Company is investigating a mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients. Ardea also is developing a next-generation NNRTI for HIV and a next-generation MEK inhibitor for both cancer and inflammatory diseases.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including the expected properties and benefits of RDEA806, RDEA119 and its other compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: Edie DeVine of WeissComm Partners, +1-415-946-1081, for ArdeaBiosciences, Inc.

Ticker Symbol: (NASDAQ-NMS:RDEA)

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: January 2008

View comments

Hide
(web1)